ANNUAL REPORT 2016-2017 · 8 \ CROSS-SECTOR BIOTECH / 9 ANNUAL REPORT 2016-2017 The 2016 European...
Transcript of ANNUAL REPORT 2016-2017 · 8 \ CROSS-SECTOR BIOTECH / 9 ANNUAL REPORT 2016-2017 The 2016 European...
ANNUAL REPORT2016-2017
STRENGTHENING BIOTECHNOLOGY AND THE EU PROJECT
The European biotechnology industry, as a key contributor to growth, jobs and innovation in all 28 EU countries, remains fully supportive of the European Project and of a strong, united and open Europe.
The Brexit vote which occurred a year ago ushered in a period of political turbulence and uncertainty which will wield a substantial impact not only on the future of European integration but also on the international community as a whole, which is why the entire world is paying close attention to the ongoing negotiations. This testifies to the expectation that the United Kingdom and the European Union (EU) will continue to lead the world in enlarging and promoting a free and open market economy. Moreover, in the international community today, where the global order is beset with challenges, the presence of a strong, united Europe is essential.
In fact, biotechnology has been a pillar of EU competitiveness and innovation for the past twenty years. Our three sectors, spanning healthcare, industrial and agricultural biotechnology, have heavily invested in the European project with a presence of over three thousand companies in Europe today, ranging from start-ups of less than ten people to multinational companies present in multiple EU countries.
This investment underpins our support for a strong, competitive Europe delivering solutions that benefit patients, farmers, other end users and citizens as a whole. At the same time, the need to boost economic recovery, access fresh investment, create new markets and cultivate a highly skilled workforce is becoming increasingly critical, if the EU is to overcome the current political turbulence and even thrive.
Bold political leadership which recognises and plays to Europe’s competitive and technological strengths rather than stifling them, is needed now more than ever, if the EU is to create a stronger, smarter Europe delivering the benefits, jobs and growth that its citizens need. Based on the work outlined in this report, EuropaBio with all its members stand ready and eager to support this ambition.
Carlo Incerti, MD
EuropaBio Chairman
TABLE OFCONTENTS
Cross-sectorbiotech
Healthcarebiotech
Agricultural biotech
Industrialbiotech
Our team Our members
7 15 21 27 32 34
CROSS-SECTORBIOTECH
In addition to priorities in the healthcare, industrial and agricultural
biotech sectors, EuropaBio works on a number of initiatives to strengthen
biotechnology in Europe. These include supporting and raising awareness
of biotech SMEs, global industry collaboration through the International
Council of Biotech Associations, and outreach projects to raise the profile
of European biotech among policymakers and the broader public.
HIGHLIGHTS
4th annual Biotech Week breaks new records
Recognising and promoting European biotech SMEs
Celebrating EuropaBio’s 20th anniversary
ICBA Global Life Sciences Ministerial-Industry Meeting
europabio.org/cross-sector
CROSS-SECTOR BIOTECH / 98 \
ANNUAL REPORT 2016-2017
The 2016 European Biotech Week, organised between 26
September and 2 October, broke new records building on
the success of 2015.
Not only did it feature in the first ever Global Biotech Week,
but it also set a new record with 16 European countries involved, including 3 newcomers:
Austria, Norway and Sweden. 135 activities and events organised across Europe involved
thousands of Europeans and ranged from open door days, symposiums, round table
discussions and competitions, to hands-on experiments and theatre shows.
4TH ANNUAL EUROPEAN BIOTECH WEEK BREAKS NEW RECORDS KEY FIGURES FOR THE WEEK INCLUDE:
11 media partners
58 media pick-ups across 11 countries
Informative events magazine
Amazing biotech history timeline
Twitter followers
#BiotechWeek tweets
visits of@biotechweek
including 38% growth over 1 week
135 events took place in 16 countr es
ON SOCIAL MEDIA
media outlets2
18 companies(including 4 EuropaBio members)
4 nationaloffices & councils
42 universities, schools & education centres
32 laboratories and research institutes
36 biotech, life sciences or business organisations(incl. 9 EuropaBio member national associations)
5museums
ALL WERE AMONG THE ORGANISERS GETTING INVOLVED IN THE WEEK
#
@
>1.600
>800
2.700
CROSS-SECTOR BIOTECH / 1110 \
ANNUAL REPORT 2016-2017
With the ‘Most Innovative European Biotech SME Awards’, now in their 7th year,
EuropaBio recognises exceptional small and medium-sized companies in Europe that
have developed novel ways of addressing our societal, technical, and environmental
problems through the application of biotechnology.
RECOGNISING AND PROMOTINGEUROPEAN BIOTECH SMES
The 2016 winners were:
The awards ceremony was the highlight of a top-level European Biotech SME Forum
attended by 12 CEOs and many other industry leaders. One of the Forum’s key
outcomes was the launch of the Call to Action for Biotech SMEs in Europe.
In addition to celebrating these exceptional SMEs, the 2016 awards were ground-
breaking in other ways too:
Agricultural biotech
category
Industrial biotech
category
Healthcare biotech
category
Plant Response Biotech,
a Spanish company
developing novel natural
products to confer
resistance and enhance
plant responses to biotic
and abiotic stress.
OxyMem, an Irish
company aiming to
revolutionise biological
aeration for industrial and
municipal wastewater
plants. The runners-up
in the industrial biotech
category were Biosyntia
and MetGen.
Cellectis, a French
biopharmaceutical
company developing
adoptive immunotherapies
for cancer. The runners-up
in the healthcare biotech
category were Oryzon
Genomics and TiGenix. 41 applications from12 countries
Plant Response Biotechwas the first ever agricultural
biotech SME prize winner.
www.biotechsmeawards.eubecame the initiative’s online
home and application hub.
CROSS-SECTOR BIOTECH / 1312 \
ANNUAL REPORT 2016-2017
We also celebrated our anniversary in other ways:
We marked the anniversary with a unique Charity Gala Dinner entitled ‘Back to the
Biotech Future’. Attended by 150 guests from industry, member companies and
associations, EU Institutions, academia, as well as former staff members, the event both
looked back at the evolution of the European biotech industry over the past twenty
years and looked forward to what the future holds. Thanks to their generosity, over
20.000€ was raised through a silent auction for an EMBO fund covering short-term
fellowships for talented researchers and their studies on systems biology and genomic
and computational science.
CELEBRATING EUROPABIO’S20TH ANNIVERSARY
In 2016, the International Council of Biotech Associations, of which EuropaBio is an
active and founding member, organised the inaugural Global Life Sciences Ministerial-
Industry Meeting entitled “How to Boost
Socio-Economic Benefits of Biotech Innovation
– Domestic Policy and Global Competition”. It
was attended by the Belgian Health Minister
Maggie De Block, the European Medicines
Agency’s Executive Director Guido Rasi, and
many other high-level representatives from
governments and biotech industries worldwide.
ICBA GLOBAL LIFE SCIENCESMINISTERIAL-INDUSTRY MEETING
We developed a special anniversary logo.
We created a Calendar of Biotech Benefits for members, stakeholders
and friends of EuropaBio.
We showcased our members in our weekly newsletter.
We retraced the history, achievements and challenges of
EuropaBio in a short video documentary.
HEALTHCAREBIOTECH
Improving patients’ access to innovative therapies is at the core of our
healthcare biotechnology membership and EuropaBio’s activities over the
past year.
In the coming year we will continue to:
• Call for enhanced patient access to healthcare biotechnology
innovations.
• Raise awareness of the value healthcare biotechnology brings to
patients, economies and societies.
• Maintain and build relationships with all relevant stakeholders to
encourage innovative policy solutions aimed at meeting patients’ needs
and addressing today’s and tomorrow’s challenges.
HIGHLIGHTS
‘Reward for Innovation’ Dinner Debate at the European Parliament
15/11/2016
European Medicines Agency – EuropaBio Information Day
22/11/2016
Buying Innovative in the Healthcare Biotech Market in Europe
Fostering the discussion on biosimilars labelling
How does Healthcare Biotech Benefit Europe?
europabio.org/healthcare-biotech
HEALTHCARE BIOTECH / 1716 \
ANNUAL REPORT 2016-2017
The EuropaBio event ‘Reward for Innovation’ successfully showcased the various
viewpoints from the European Parliament, the European Commission, the Permanent
Representation of the Netherlands to the EU and the biotech industry on the challenges
and opportunities surrounding increased access to innovative healthcare products for
patients. In particular, it was highlighted that patients are at the centre of this debate
especially in areas of unmet medical needs such as rare diseases. There was a clear overall
wish from the audience and speakers to maintain the momentum of the debate with
EuropaBio’s help.
‘REWARD FOR INNOVATION’ DINNER DEBATE ATTHE EUROPEAN PARLIAMENT 15/11/2016
EUROPEAN MEDICINES AGENCY – EUROPABIO INFORMATION DAY 22/11/2016
The fourth EMA-EuropaBio Information Day took place in London.
Stakeholders discussed three main topics:
The full report of the Information Day
is available on the EMA website.
International Cooperation
with Medicines Agencies
Innovation and
Development Support
Evidence Generation During
Medicinal Life-Cycle
1 2 3
HEALTHCARE BIOTECH / 1918 \
ANNUAL REPORT 2016-2017
Stakeholders agree that there is room for improving the labelling of biosimilars in
the EU. These were the overall conclusions of a workshop bringing together patients,
pharmacists and physicians that EuropaBio organised with the Association of
European Biopharmaceutical Enterprises in early 2016. A high-level summary of the
discussions was published in the GaBI Journal in early 2017. EuropaBio believes that
minor changes to biosimilar labelling in Europe will increase transparency and help to
facilitate physicians and patients’ understanding and acceptance of biosimilars.
In March 2017, EuropaBio released an
animated video showcasing the value of
healthcare biotechnology by creating and
delivering innovative treatments and
preventive interventions for the benefit
of patients and healthcare systems across
Europe. The achievements outlined in
this video reinforce the European biotech
industry’s commitment to continue
delivering innovative therapies that
improve patients’ lives, and to work with policymakers to
ensure the sustainability of Europe’s healthcare systems
while fostering biotech innovation. The video can be
found on the EuropaBio website.
FOSTERING THE DISCUSSION ON BIOSIMILARS LABELLING
HOW DOES HEALTHCARE BIOTECHBENEFIT EUROPE?
The adoption of the new European legislative package for public procurement in
February 2014 established a more efficient and flexible framework for the public
procurement of goods, works and services across the Union. This EuropaBio paper,
published in February 2017, proposes key steps to consider when purchasing biological
medicines, looking at each stage of the procurement process. It describes how the sound
use of public procurement can drive demand for and provision of innovative biological
medicines. Ultimately, it aims to identify how institutions and purchasing authorities can
facilitate competitive market demand for healthcare innovation in Europe.
‘BUYING INNOVATIVE’ IN THE HEALTHCAREBIOTECH MARKET IN EUROPE
AGRICULTURALBIOTECH
Genetically modified (GM) crops have been widely grown and consumed
for 20 years. EuropaBio has been working hard to communicate their
benefits and remove unnecessary barriers to GMOs, including GM grain
and soybean imports into the EU, and to promote EU farmers’ freedom of
choice. Improved regulatory certainty and better implementation of the
EU’s existing GMO authorization process are urgently needed to avoid
disruptions in the trade of much needed protein-rich animal feed.
HIGHLIGHTS
Unshackling Innovation
For a workable and predictable GMO authorisation system
Politics should not continue to trump science
Communicating about GMOs in Europe
europabio.org/agricultural-biotech
AGRICULTURAL BIOTECH / 2322 \
ANNUAL REPORT 2016-2017
Supporting the EU’s own best science is critical for growth, innovation, and
investment. As various technologies for plant breeding and beyond are facing
political barriers in Europe, we joined forces with public researchers (PRRI) to
co-host the event “Unshackling Innovation: Will Europe block or enable GM crops?”
(27 September 2016, European Parliament) as part of European Biotech Week.
The event featured distinguished speakers such as Nobel laureate Sir Richard
Roberts and World Food Prize laureate Marc Van Montagu.
Together with partners in the Agri-Food Chain Coalition we continued to promote
innovation and consistency with some of the EU’s overarching policies.
UNSHACKLING INNOVATION
2016 marked the 20th anniversary of GM crop cultivation globally.
Despite an impeccable record of safe use and the many proven
societal benefits around the world, the process for granting market
authorisations to GMOs for import and cultivation in the EU remains
very politicised, very lengthy and highly unpredictable. In recognition
of the need to continuously raise broader awareness of these
problems in Europe, EuropaBio has been working together with
other stakeholders to help communicate to decision makers the
need to address inefficiencies in the EU’s risk assessment and risk
management procedures.
FOR A WORKABLE AND PREDICTABLE GMO AUTHORISATION SYSTEM
This year, EuropaBio has been leading the way as a partner in a multi-association
coalition, which has been calling on EFSA to deliver a well-structured and science-
based risk assessment process for GMOs within reasonable timeframes. Likewise, on
the risk management side, we united the voice of all interested parties and call for a
well-functioning and timely authorisation procedure for safety-assessed products, as
required by EU law.
Presentations, videos and pictures
from the ‘Unshackling Innovation’
event, which was relayed on Twitter,
can be found on the PRRI website
and on Flickr.
AGRICULTURAL BIOTECH / 2524 \
ANNUAL REPORT 2016-2017
EuropaBio is concerned about post-truth politics in the area of GMOs and continues to
encourage Member States and the European Parliament to support the EU approval of
safe products, in line with the scientific evidence. We have also criticised recent policy
choices of the European Commission, which would make the EU’s access to agricultural
biotechnology even more difficult. In view of a new Commission proposal from February
2017 revising the decision-making rules for granting product authorisations, we warned,
together with 17 partner associations, that the EU must not pursue reforms at the
expense of innovation and the single market’s integrity.
POLITICS SHOULD NOT CONTINUE TO TRUMP SCIENCE
Communicating about GM crops and policies in the EU is not easy, but the Green G-Nome
can help. Our new and comprehensive pocket guide was published in April 2017. Covering
many facets of GMOs in Europe, the new guide is an essential communications tool that
we are promoting widely on social media. It complements and includes links to our series
of factsheets about the GMO approval process, risk assessment timelines, the benefits of
GM trade, voting behavior, and the danger of import bans. We think it is time for Europe
to face the facts on GMOs in the EU.
COMMUNICATING ABOUT GMOS IN EUROPE
EuropaBio continues to raise awareness and appreciation of the role of
Industrial Biotech as an enabler of a circular, bioeconomy for Europe which
is adding value, boosting competitiveness and fostering jobs, sustainable
economic growth and investment.
Active in numerous high level fora, the Association continues to foster
collaboration with other stakeholders, develop messaging and provide
intelligence on the role of white biotech in addressing some of Europe’s
most critical challenges. These include the provision of food, feed, fuel,
chemicals and other essential everyday materials for a growing, global
population through the development of renewable products and processes
which use resources more efficiently.
Contributing to numerous high-level events, expert groups and panels,
which seek to overcome barriers to the commercialisation of EU bio-based
solutions, EuropaBio has also focused on several core activities over the
last 12 months with the aim of ensuring greater deployment of industrial
biotechnology and access to its accompanying benefits.
HIGHLIGHTS
European Bioeconomy Alliance
New study shows jobs and growth generated by Industrial Biotech on the rise
EFIB 2016
18/10/2016 - 20/10/2016
DG GROW Bio-Based Products Expert group workshop
02/12/2016
Moving towards a Circular Bioeconomy in Europe
INDUSTRIALBIOTECH
europabio.org/industrial-biotech
INDUSTRIAL BIOTECH / 2928 \
ANNUAL REPORT 2016-2017
EuropaBio is playing a very active role in the work of the European Bioeconomy Alliance.
Comprised of 12 leading European organisations, the Alliance advocates for the creation
of a more favourable and supportive environment for the development of a world
leading, sustainable and competitive bioeconomy in Europe, while raising awareness of
the bio-based sectors and their benefits.
EUROPEAN BIOECONOMY ALLIANCE
MEPs Lambert van Nistelrooij and Franc Bogovič hosted the report
launch event in the European Parliament and EuropaBio continues to
actively share the findings of the study in external events, with policy
makers and other stakeholders.
Industrial Biotech contributes over €30 billion to the EU economy and around
500.000 jobs, with figures expected to grow to between 900.000-1.5 million jobs
with an accompanying economic contribution of up to almost €100 billion by 2030.
Those were the key findings of a new EuropaBio report, prepared to highlight the
increasing potential of Industrial Biotech to contribute towards Europe’s jobs, growth
and competitiveness agenda, which was commissioned and prepared by EuropaBio,
published in September 2016.
NEW STUDY SHOWS JOBS AND GROWTH GENERATED BY INDUSTRIAL BIOTECH ON THE RISE
bioeconomyalliance.eu
INDUSTRIAL BIOTECH / 3130 \
ANNUAL REPORT 2016-2017
>500attendeesexhibition space
The Expert Group held a workshop on the sustainability of bio-based products,
coordinated by EuropaBio. With participation of officials from the Commission, Member
States, European Parliament and other stakeholders, the workshop aimed to enable an
open and informed discussion on several themes around the sustainability of bio-based
products. The workshop was a great success in attendance with approximately
75 participants, with much interest and active discussions.
Rather than developing the circular economy and the bioeconomy in parallel, greater
integration will contribute with benefits for the environment, economy and society.
EuropaBio is actively advocating for a greater emphasis on the interlinkages between the
two, inter alia through its work in the context of the European Bioeconomy Alliance, the
EU Bioeconomy Stakeholders Panel and ongoing collaboration with other organisations.
DG GROW BIO-BASED PRODUCTS EXPERT GROUP WORKSHOP 02/12/2016
MOVING TOWARDS A CIRCULAR BIOECONOMYIN EUROPE
EuropaBio’s Congress on Industrial Biotech and the Bioeconomy, EFIB, has grown from 80
people in 2008 to over 500 people in 2016. It provides a meeting place for the entire
bio-based value chain, enabled by industrial biotech, and draws together influencers and
thought leaders from business, policy and beyond. Preparations for EFIB 2017 in the SQUARE
Brussels from 9-11 October are well underway – we look forward to seeing you there.
EFIB 2016 18/10/2016 - 20/10/2016
and a SOLDOUT
35from over
countr es
LAST YEAR’S CONGRESS TOOK PLACE IN GLASGOW, SCOTLAND AND FEATURED:
Several wellattended
networkingevents.
Approximately
100 HIGH-LEVELSPEAKERS
including Dame Anne Glover & Paul Gilding, representatives from the European Commission, IKEA, P&G, Unilever, PSA Group, Tetra Pak, Ecover, Ellen MacArthur Foundation, Celtic Renewables and many more.
First ever EFIB ‘pitchfest‘ won by MetGen awarded
by a panel of Venture Capitalists for most
promising new product or process.
Numerous session tracks on forging the
link between the circular economy and the
bioeconomy, feedstocks of the future, innovation, international and regional
strategy development, brand owners and climate
change mitigation.
3F-Bio revealed as winners of coveted John Sime award for innovation.
OUR TEAM / 3332 \
ANNUAL REPORT 2016-2017
OUR TEAMJohn Brennan
Secretary General Since June 2017
Nathalie MollSecretary General Until March 2017
Joanna Dupont-InglisDirector, Industrial
Biotechnology
Cosmin PopaManager, Communications
& National Associations
Mélanie MoxhetCommunications & Office
CoordinatorUntil November 2016
Davide MarchiManager, Healthcare
BiotechnologySince December 2016
Delphine CarronRegulatory Affairs Manager, Agricultural Biotechnology
Until March 2017
Clément RobijnsCommunications & Office
CoordinatorSince November 2016
Riccardo MezzasalmaManager, Healthcare
BiotechnologyUntil September 2016
Violeta GeorgievaLegal and Regulatory Manager,
Agricultural Biotechnology
Petra KostolaniovaRegulatory Affairs Officer,Agricultural Biotechnology
Since March 2017
Ronald JagerDirector, Healthcare
BiotechnologySince August 2016
Pedro Narro SanchezPublic Affairs Manager,
Agricultural Biotechnology
Christopher GallaschCommunications Manager,Agricultural Biotechnology
Alexander GibbsManager, Healthcare
Biotechnology
Christine DevauxIT Manager &
PA to the Secretary General
Beat SpäthDirector, Agricultural
Biotechnology
Catherine De FeyterDirector, Finance, HR & Office Administration
Agnes BorgManager, Industrial
Biotechnology
OUR MEMBERS / 3534 \
ANNUAL REPORT 2016-2017
OUR MEMBERSOur membership includes a wide range of corporate members and industry associations
involved in biotechnology throughout Europe. EuropaBio has 50 corporate and
27 associate members and BIO Regions and 16 national biotechnology associations –
representing some 1800 small and medium-sized enterprises across Europe.
AbbVie
Ajinomoto Eurolysine
Alexion
ARD
Amgen
Areta International
BASF
Bayer
Bio Amber
Biogen
Biomarin
Carbios
Clariant
Corbion
CSL Behring
Clementia Pharmaceuticals
Dow AgroSciences
DuPont
Eli Lilly
Erytech
Evonik Industries
Horizon Pharma
Intrexon Actobiotics
Keygene
KWS SAAT SE
Knowledge Transfer Network Ltd
Limagrain
Merck KGaA
Monsanto
Merck & Co
NatureWorks
Novamont
Novartis
Novo Nordisk
Novozymes
Nestec
Orphan Europe
Pfizer
PTCBIO
Royal DSM
Roquette
Shire
SOBI
Solvay
Syngenta
Sanofi Genzyme
Transgene
UniQure
Vertex Pharmaceuticals
2-BBB Medicines
Biosyntia
Bluebird Bio
Cambridge Biomedical
Consultants
Celtic Renewables
Cellectis
Deerfield
Dr. Regenold
Expert Services & Advice in
Healthcare BVBA
EORTC
Iden
Intellia Therapeutics
Kedrion Biopharma
MolMed
MetGen
Nanobiotix
Oryzon Genomics
OxyMem
Perseus
Plant Response Biotech
Redx Pharma
SFL Pharma
Svanvid
TNO
TiGenix
Voisin Consulting Life Sciences
Italy | Assobiotec Federchimica
Spain | Asebio
Belgium | Bio.be
Germany | Bio Deutschland
Ireland | BioPharmaChem
UK | Bioindustry Association
Denmark | Dansk Biotek
Germany | DIB
Finland | Finnish Bioindustries
France | France Biotech
The Netherlands | HollandBIO
Norway | Norwegian Bioindustry Association
Portugal | P-BIO
Sweden | SwedenBio
Switzerland | Swiss Biotech Association
Switzerland | Scienceindustries
CORPORATE MEMBERS
ASSOCIATE MEMBERS AND BIO REGIONS
NATIONAL ASSOCIATIONS
EuropaBio aisbl Avenue de l’Armée 6, 1040 Brussels, Belgium
t. +32 2 735 03 13 | f. +32 2 735 49 60
www.europabio.org